Vanguard Group Inc Monopar Therapeutics Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
A detailed history of Vanguard Group Inc transactions in Monopar Therapeutics stock. As of the latest transaction made, Vanguard Group Inc holds 45,167 shares of MNPR stock, worth $38,843. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,167
Previous 45,167
-0.0%
Holding current value
$38,843
Previous $15,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding MNPR
# of Institutions
16Shares Held
390KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny192KShares$165,4470.0% of portfolio
-
Geode Capital Management, LLC Boston, MA41.2KShares$35,4310.0% of portfolio
-
Hrt Financial LP New York, NY32.1KShares$27,6170.0% of portfolio
-
Gerber, LLC Columbus, OH28KShares$24,0840.02% of portfolio
-
Virtu Financial LLC New York, NY23.8KShares$20,4910.0% of portfolio
About Monopar Therapeutics
- Ticker MNPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,725,800
- Market Cap $10.9M
- Description
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...